Simon T, et al. N Engl J Med 2009;360:363-75

Slides:



Advertisements
Similar presentations
David N. Juurlink, et al. CMAJ 2009;180: (7) [Epub]
Advertisements

Hepatic generation of active metabolite Pharmacogenetics of Cardiovascular Antithrombotic Therapy CYP = cytochrome P450. GP = glycoprotein. MDR = multidrug.
Prasugrel Background and PRINCIPLE – TIMI 44 Stephen D. Wiviott, MD Cardiovascular Division Brigham and Women’s Hospital Assistant Professor of Medicine.
ADP Receptors Bhatt DL et al. Nature Reviews Drug Discovery 2003; 2:15-28.
Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.
Ticlopidine (Ticlid™) and Clopidogrel (Plavix™) Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.
S. Banai, M.D. Loading dose with Clopidogrel before PCI How high should we go? Shmuel Banai, MD Director, Interventional Cardiology Tel Aviv Medical Center.
Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary.
Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:
The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]
ANTIPLATELETES AGENTS
Mechanism of Action of Aspirin Carlo Patrono, et al, N Engl J Med 2005;353:
The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:
Baseline Characteristics of Patients Referred for Stress Myocardial Perfusion Testing by Erectile Function Classification James K. Min, et al, Arch Intern.
Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.
- Published online December 23, 2008 DOI: /S (08) Study sponsored and funded by Assistance Publique.
Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]
Schematic of the single variant polymorphism (SNP) genotyping assay.
Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:
Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduced-Function CYP2C19 Genotype and Risk of Adverse.
Mega JL, et al. N Engl J Med 2009;360: Genetic Effects on Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel Mega JL, et al. N Engl J.
(p for noninferiority = 0.01)
Discontinuation of medication after nonfatal event: MI
New Anti-platelet Agents
The SPRINT Research Group
Peng Yin1, Andrea L Jorgensen1, Andrew P Morris1, Richard Turner2, Richard Fitzgerald2, Rod Stables3, Anita Hanson2, Munir Pirmohamed2 1. Department of.
Structure of Cis and Trans Fatty Acids
Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study
The Evaluation of CYP2D6, CYP2C9 and CYP2C19 Polymorphisms for Personalized Medicine in Psychiatry Patients Ebru DÜNDAR YENILMEZ1, Onur KARAYTUG2, Lut.
Genetic Testing for the Clinician
Clopidogrel Pharmacogenetics: Ready for Prime-Time?
Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.
Genotyping: Which One Should we Perform? How to Interpret the Data?
The GRAVITAS trial Matthew J. Price MD, FACC, FSCAI
The Evaluation of CYP2D6, CYP2C9 and CYP2C19 Polymorphisms for Personalized Medicine in Physiciatry Patients Ebru DUNDAR YENILMEZ1, Onur KARAYTUG2, Lut.
Med Chem Tutoring for Anticoagulants, Antiplatelets, and Thrombolytics
We Should Tailor Antiplatelet Therapy Based on Platelet Function Testing and Genotyping Paul A. Gurbel Sinai Center for Thrombosis Research Baltimore,
TNT: Baseline and final LDL cholesterol levels
11/12/2018 CYP2C19-Clopidogrel Development of these slides was supported by funding from the IGNITE Network. When using or adapting any of these slides.
11/12/2018 CYP2C19-Clopidogrel Development of these slides was supported by funding from the IGNITE Network. When using or adapting any of these slides.
Mandeep Singh, MD, MPH, Deepak L. Bhatt, MD, MPH, Gregg W
Baseline characteristics of patients
Study Design Ketil Lunde, et al. N Engl J Med 2006;355:
Becker RC, et al. Lancet 2009;373:919-28
Fellström BC, et al. N Engl J Med 2009;360:1455-7
Orlando, March , American College of Cardiology
Pharmacogenetics and Pharmacoepidemiology “PHCY 480”
Enrollment and Outcomes
Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,
Baseline Characteristics According to Sex
Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:
Baseline Characteristics of the Study Participants
Baseline Characteristics of the Subjects*
Women’s Health Study: Baseline Characteristics Part 1
Collet JP, et al. Lancet 2009;373:309-17
Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:
Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,
Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.
Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)
Baseline Characteristics of the Patients – Part I
Baseline Characteristics by hs-CRP
Baseline Characteristics of the Patients - Part I
The ACCORD Study Group. NEJM 2010; Epub March 14
Comparison of Baseline Characteristics by Primary End Point
EMPA-REG OUTCOME: Cumulative incidence of the primary outcome
Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:
Christian Madelaire et al. JCHF 2018;6:
Ticagrelor: agonising over its mechanisms of action
Presentation transcript:

Simon T, et al. N Engl J Med 2009;360:363-75

Roles in Clopidogrel Activity of Proteins with Known Genetic Polymorphisms Intestinal absorption of the prodrug clopidogrel is limited by an intestinal efflux pump P-glycoprotein coded by the ABCB1 gene. The majority of the prodrug is metabolized into inactive metabolites by ubiquitous esterases. The minority is bioactivated by various cytochrome P450 (CYP) isoforms into active metabolites. These metabolites irreversibly antagonize the adenosine diphosphate (ADP) receptor (coded by the P2RY12 gene), which in turn inactivates the fibrinogen receptor (the glycoprotein [GP] IIb/IIIa receptor coded by the ITGB3 gene) involved in platelet aggregation. Simon T, et al. N Engl J Med 2009;360:363-75

Baseline Characteristics of the Study Patients* Simon T, et al. N Engl J Med 2009;360:363-75

Characteristics of In-Hospital Care of the Study Patients* Simon T, et al. N Engl J Med 2009;360:363-75

Allelic Frequencies of SNPs among the Study Patients, According to Gene – Part I Simon T, et al. N Engl J Med 2009;360:363-75

Allelic Frequencies of SNPs among the Study Patients, According to Gene – Part II Simon T, et al. N Engl J Med 2009;360:363-75

of Variant-Allele Polymorphisms Rates of Death from Any Cause, Nonfatal Myocardial Infarction, or Stroke, According to Characteristics of Variant-Allele Polymorphisms Panel A shows outcomes according to the type of ABCB1 C3435T alleles present; Panel B shows outcomes according to the number of CYP2C19 loss-of-function alleles. The inset graph in each panel shows the same curves on a larger scale. The P values were calculated with the use of multivariate Cox analysis. MI denotes myocardial infarction. Simon T, et al. N Engl J Med 2009;360:363-75

Predictors of Death from Any Cause, Nonfatal Myocardial Infarction, or Stroke among the Study Patients Simon T, et al. N Engl J Med 2009;360:363-75

Methods and reaction conditions used for genotyping Simon T, et al. N Engl J Med 2009;360:363-75 Supp App

Characteristics of patients in the propensity-matched cohort Simon T, et al. N Engl J Med 2009;360:363-75 Supp App